Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 208,731 Shares

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd sold 208,731 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $8.09, for a total transaction of $1,688,633.79. Following the completion of the sale, the insider directly owned 7,347,452 shares in the company, valued at approximately $59,440,886.68. The trade was a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Friday, July 24th, L1 Capital Pty Ltd sold 23,000 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.13, for a total value of $186,990.00.

Anteris Technologies Global Stock Performance

Shares of NASDAQ:AVR opened at $8.17 on Wednesday. Anteris Technologies Global Corp. has a 12-month low of $2.99 and a 12-month high of $11.06. The business has a 50 day moving average of $9.28 and a two-hundred day moving average of $7.09. The company has a market capitalization of $795.28 million, a PE ratio of -3.66 and a beta of 1.65.

Anteris Technologies Global (NASDAQ:AVR) last posted its earnings results on Tuesday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.77 million. Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. During the same quarter in the prior year, the firm earned ($0.61) earnings per share. Equities research analysts predict that Anteris Technologies Global Corp. will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. acquired a new position in shares of Anteris Technologies Global during the 2nd quarter valued at about $6,350,000. Militia Capital Management LLC purchased a new stake in shares of Anteris Technologies Global in the first quarter valued at about $3,663,000. Perceptive Advisors LLC increased its position in Anteris Technologies Global by 104.4% during the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after purchasing an additional 1,750,000 shares during the last quarter. Avidity Partners Management LP acquired a new stake in Anteris Technologies Global during the first quarter worth about $832,000. Finally, Bank of America Corp DE raised its stake in Anteris Technologies Global by 12.6% during the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock worth $382,000 after purchasing an additional 7,688 shares during the period.

Wall Street Analyst Weigh In

AVR has been the topic of several recent analyst reports. Barclays increased their target price on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Friday, May 29th. Finally, Wall Street Zen upgraded Anteris Technologies Global from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.